Evidence map›Paper›PMID 35904711›Full record

ReviewProgress in biomaterials2022

Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis.

Cristina Quispe, Jesús Herrera-Bravo, Khushbukhat Khan, Zeeshan Javed, Prabhakar Semwal, Sakshi Painuli, Senem Kamiloglu, Miquel Martorell, Daniela Calina, Javad Sharifi-Rad

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Progress in biomaterials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Oxidative medicine and cellular longevity · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 6 countries.

Cristina QuispeFacultad de Ciencias de La Salud, Universidad Arturo Prat, Avda. Arturo Prat 2120, 1110939, Iquique, Chile.
Jesús Herrera-BravoDepartamento de Ciencias Básicas, Facultad de Ciencias, Universidad Santo Tomas, Bogotá, Chile.
Khushbukhat KhanDepartment of Healthcare Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Sector H-12, Islamabad, 44000, Pakistan.
Zeeshan JavedCenter for Applied Molecular Biology, University of the Punjab, Lahore, Pakistan.
Prabhakar SemwalDepartment of Biotechnology, Graphic Era University, Dehradun, India.
Sakshi PainuliDepartment of Biotechnology, Graphic Era University, Dehradun, India.
Senem KamilogluScience and Technology Application and Research Center (BITUAM), Bursa Uludag University, 16059, Gorukle, Bursa, Turkey.
Miquel MartorellDepartment of Nutrition and Dietetics, Faculty of Pharmacy, and Centre for Healthy Living, University of Concepción, 4070386, Concepción, Chile. mmartorell@udec.cl.
Daniela CalinaDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania. calinadaniela@gmail.com.
Javad Sharifi-RadFacultad de Medicina, Universidad del Azuay, Cuenca, Ecuador. javad.sharifirad@gmail.com.ORCID http://orcid.org/0000-0002-7301-8151
Arturo Prat University · CLBursa Uludağ Üni̇versi̇tesi̇ · TRGraphic Era University · INNational University of Sciences and Technology · PKUniversidad de La Frontera · CLUniversidad del Azuay · ECUniversity of Concepción · CLUniversity of Medicine and Pharmacy of Craiova · ROUniversity of the Punjab · PKUttarakhand State Council for Science and Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medicinal applications of turmeric-derived curcumin have been known to mankind for long ages. Its potential in managing "cystic fibrosis" has also been evaluated. This autosomal recessive genetic disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) which involves an impaired secretion of chloride ions and leads to hypersecretion of thick and sticky mucus and serious complications including airway obstruction, chronic lung infection, and inflammatory reactions. This narrative review aims to highlight the available evidence for the efficacy of curcumin nanoformulations in its potential treatment of cystic fibrosis. Recent research has shown that curcumin acts on the localized mutant CFTR ion channel at the plasma membrane. Preclinical studies have also shown that curcumin nanoformulations have promising effects in the treatment of cystic fibrosis. In this context, the purpose of this narrative review is to highlight the general bioactivity of curcumin, the types of formulations and related studies, thus opening new therapeutic perspectives for CF.

Indexed as

BioavailabilityCurcumin nanoparticlesCystic fibrosisMolecular mechanismsSignalling pathways

Identifiers

PMID35904711
PMCPMC9626725
OpenAlexW4288514214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.